within Pharmacolibrary.Drugs.ATC.C;

model C05CX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 3.3333333333333335e-05,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C05CX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Naftazone is a vasoactive drug formerly used for the treatment of peripheral vascular diseases, including chronic venous insufficiency and hemorrhoids, mainly in some European and Asian countries. It is a derivative of naphthoquinone. The use of naftazone has declined and it is not widely approved or available in many markets today.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameters for naftazone were identified in literature databases. The following are estimated parameters for a typical adult after oral administration.</p><h4>References</h4><ol><li><p>Delwaide, PA, et al., &amp; Heusghem, C (1974). [The pharmacokinetics of naftazone-3H]. <i>Archives internationales de pharmacodynamie et de therapie</i> 208(2) 357–361. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4849939/\">https://pubmed.ncbi.nlm.nih.gov/4849939</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C05CX02;
